High procalcitonin typically indicates a systemic bacterial infection or sepsis: levels rise with severe bacterial inflammation and correlate with infection severity and prognosis. It helps distinguish bacterial from viral causes and can guide starting or stopping antibiotics. Some noninfectious conditions (major trauma, surgery, burns, certain cancers) and renal dysfunction may also elevate procalcitonin, so interpret with clinical context.

Procalcitonin is a blood biomarker that rises sharply in systemic bacterial infections and sepsis, often within a few hours, and correlates with infection severity. It helps distinguish bacterial from viral causes, guides initiation and early discontinuation of antibiotics, and monitors treatment response. Results must be interpreted alongside clinical assessment and other investigations because levels can be influenced by noninfectious factors and sampling time.

Procalcitonin (PCT) levels guide sepsis likelihood: <0.25 ng/mL makes bacterial sepsis unlikely; ≥0.5 ng/mL raises suspicion; ≥2 ng/mL strongly suggests sepsis or severe bacterial infection, with very high levels (e.g., >10 ng/mL) seen in severe sepsis/septic shock. Clinical context and serial measurements are essential—single values should be interpreted alongside signs, cultures, and other investigations.

Procalcitonin (PCT) and C‑reactive protein (CRP) are blood biomarkers of inflammation. PCT is more specific for bacterial infection, rises earlier (within about 6–12 hours), and better reflects bacterial severity and guides antibiotic decisions. CRP is a general acute‑phase reactant produced by the liver, less specific, rises more slowly (peaks around 24–48 hours), and increases with many inflammatory or tissue‑injury conditions.

Procalcitonin is mainly a marker of bacterial infection but can be elevated in certain cancers. Markedly raised levels occur in medullary thyroid carcinoma and other neuroendocrine tumors (including small‑cell lung cancer). Moderate increases may be seen with advanced metastatic solid tumors (lung, breast, gastrointestinal), hematologic malignancies, and extensive tumor necrosis or tumor‑related systemic inflammation; concomitant infection greatly amplifies PCT.

Procalcitonin falls when the underlying bacterial infection is treated and inflammation is controlled. Key steps: prompt targeted antibiotics guided by cultures and stewardship, adequate source control (drain abscesses, remove infected devices), intensive supportive care for sepsis, and regular PCT monitoring to guide antibiotic duration. Clinical improvement plus declining PCT supports stopping antibiotics; follow your clinician’s guidance.